Bayer AG has made its first filing for elinzanetant, trumpeted as a key growth driver for its pharma division in the coming years, just as Astellas Pharma, Inc.'s rival non-hormonal treatment for menopausal symptoms looks to have turned a corner commercially.
Bayer Moves Closer To Astellas With Menopause Drug Filing
As sales of the Japanese drugmaker’s non-hormonal treatment for menopausal symptoms Veozah finally take off, the German major has filed its potential competitor, elinzanetant, with the US Food and Drug Administration.
More from Women's Health
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.